Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News INmune Bio Inc INMB

Healthcare Biotechnology
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. It has two therapeutic platforms: a Dominant-Negative Tumor Necrosis Factor Platform (DN-TNF, XPro, XPro1595 or pegipanermin) and a Natural Killer (NK or INKmune) platform. The DN-TNF product platform utilizes dominant-negative technology to... see more

Recent & Breaking News (NDAQ:INMB)

XPro1595 Improves Outcomes in a Mouse Model of TBI-induced Alzheimer's Disease

GlobeNewswire April 19, 2023

INmune Bio, Inc. to Present Preclinical Data at the 2023 AACR Annual Meeting Showing Improved Outcomes in High-Risk Breast Cancer by Targeting MUC4 Expression with INB03

GlobeNewswire April 11, 2023

INmune Bio, Inc. Announces Submission of Investigational New Drug (IND) Application for INKmune(TM) to the U.S. Food and Drug Administration for Treatment of Metastatic Castration-Resistant Prostate Cancer

GlobeNewswire April 3, 2023

INmune Bio, Inc. Announces 2022 Results and Provides Business Update

GlobeNewswire March 2, 2023

INmune Bio, Inc. to Report Fourth Quarter and Full-Year 2022 Results and Provide a Corporate Update on Thursday, March 2

GlobeNewswire February 21, 2023

INmune Bio, Inc. Receives Approximately $6.4 Million in Research and Development Rebates from Australia and the United Kingdom

GlobeNewswire February 8, 2023

INmune Bio, Inc. Announces Pre-Clinical Data That Support a Pioneering Approach to Treating Duchenne Muscular Dystrophy

GlobeNewswire January 25, 2023

INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer's Disease

GlobeNewswire December 22, 2022

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune(TM)

GlobeNewswire December 8, 2022

INmune Bio, Inc. Reports Combination Therapy with INB03(TM) Overcomes Resistance to Trastuzumab-Deruxtecan in MUC4 expressing HER2+ Breast Cancer

GlobeNewswire December 6, 2022

INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer's Disease Treatments

GlobeNewswire November 29, 2022

INmune Bio, Inc. Receives Health Canada "No Objection Letter" to Commence Clinical Trial of XPro1595 in Mild Alzheimer's Disease

GlobeNewswire November 14, 2022

INmune Bio, Inc. Announces Third Quarter 2022 Results and Provides Business Update

GlobeNewswire November 2, 2022

INmune Bio, Inc. to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, November 2

GlobeNewswire October 26, 2022

INmune Bio, Inc. Announces Positive Solid Tumor Efficacy Data in Multiple Cancer Cell Lines for INKmune

GlobeNewswire October 19, 2022

INmune Bio, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference and the Baird Global Healthcare Conference

GlobeNewswire September 7, 2022

INmune Bio, Inc. Announces Second Quarter 2022 Results and Provides Business Update

GlobeNewswire August 3, 2022

INmune Bio, Inc. to Report Second Quarter 2022 Financial Results and Provide a Corporate Update on Wednesday, August 3

GlobeNewswire July 27, 2022

INmune Bio, Inc. CEO, Raymond J. Tesi, MD, to Participate in Two Upcoming Panels on Alzheimer's Disease

GlobeNewswire July 25, 2022

USPTO Issues Patent Covering Use of XPro(TM) for Treatment of CNS Diseases

GlobeNewswire June 22, 2022